ZOLADEX LA acts as a gonadotropin-releasing hormone (GnRH) agonist, causing prolonged suppression of testosterone and estrogen secretion. This slows the progression of hormone-dependent tumors. Recommended for:
Patients with progressive prostate cancer
Women with hormone-dependent breast cancer
Adjuvant therapy post-surgery
Symptom control during disease management
Treatment of progressive prostate cancer
Hormone-dependent breast cancer in women
Preoperative preparation and adjuvant therapy in indicated conditions
Administered subcutaneously or intramuscularly by a healthcare professional every 12 weeks. Dosage and treatment duration are individualized based on patient condition and disease progression.
Hypersensitivity to goserelin or formulation components
Pregnancy and breastfeeding
Caution in severe liver or kidney disease
Side effects include hot flashes, headache, fatigue, decreased libido, joint pain, injection site reactions
